A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Sep 30, 2021
  • participants needed
    115
  • sponsor
    Eisai Inc.
Updated on 22 June 2021
Investigator
Eisai Medical Information
Primary Contact
Auxilio Mutuo Cancer Center (2.6 mi away) Contact
+22 other location

Summary

The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.

Description

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent CTCL. The study consists of an initial Lead-in part (to select recommended dose of E7777 for Main part), followed by the Main part (to test efficacy). Lead in part is complete and main study is ongoing. Participants will move through three phases while on study: Pretreatment Phase, Treatment Phase, and Extension Phase and a Follow-up Period.

Details
Condition Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma, Persistent or Recurrent Cutaneous T-Cell Lymphoma
Treatment E7777, E7777 9 mcg/kg
Clinical Study IdentifierNCT01871727
SponsorEisai Inc.
Last Modified on22 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants must meet all of the following criteria to be included in the
study
Age greater than or equal to 18 years
Histopathologic diagnosis of CTCL (mycosis fungoides [MF] or Sezary Syndrome [SS]), confirmed by skin biopsy, or lymph node, or blood assessment, of current disease
CD25 assay-positive tumor, defined as detectable CD25 on greater than or equal to 20% of total lymphoid infiltrate in biopsied lesions by immunohistochemistry
CTCL disease stage at study entry as follows, according to ISCL/EORTC (Olsen 2011)
Lead-In Part: Stage IA - IV, except participants with CNS involvement
Main Study: Stage I - III
History of prior therapies for CTCL: must have had prior therapy, any number of prior therapies allowed
Topical treatments (except topical chemotherapy) and steroids are not
considered as prior therapies
\. A minimum washout period of 4 weeks after previous CTCL therapy is
recommended before the first dose of E7777
Participants must have recovered from any adverse effects from any previous
CTCL therapy to Common Terminology Criteria for Adverse Events (CTCAE) Grade
<2 before starting study drug. A shorter washout may be allowed if participant
is experiencing progressive disease despite ongoing treatment
\. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 in
the Lead-In Part and performance status of 0 or 1 in the Main Study
\. Life expectancy greater than or equal to 3 months in the Lead-In Part and
greater than or equal to 12 months in the Main Study
\. Adequate bone marrow reserves as evidenced by
platelets greater than or equal to 100,000/mm^3 (100 x 10^9/L)
clinically stable hemoglobin greater than or equal to 9 gram per deciliter (g/dL) (90 g/L) and hematocrit greater than or equal to 27% without transfusion support 10. Normal hepatic function as evidenced by
bilirubin <= 1.5 _upper limit if normal (ULN) and alkaline phosphatase <=3.0_ULN
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0ULN
albumin >= 3.0 g/dL (30 g/L) 11. Adequate renal function as evidenced by serum creatinine less than or equal to 1.8 mg/dL (158 umol/L) or calculated creatinine clearance greater than or equal to 50 mL/min (per the Cockcroft-Gault formula) with less than 2+ protein or 24- hour urine creatinine clearance greater than or equal to 50 mL/minute with 24- hour urine protein less than 1gram. 12. Provide written informed consent prior to any study-specific screening procedures. 13. Females may not be lactating or pregnant at Screening or Baseline 14. All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically 15. Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partner must meet the criteria above

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the
study
Prior denileukin diftitox therapy
Use of topical steroids within 14 days of Day 1 of initial therapy is not allowed.Topical steroids or systemic low dose steroids of less than or equal to 10 milligram per day (mg/day) prednisone are allowed in participants with erythroderma who have been on corticosteroids for a prolonged period of time and where discontinuation may lead to rebound flare in disease. The concomitant steroid medication is allowed as long as the type of steroid, route of administration, and steroid dose remain the same as what the participant had been receiving for a prolonged period of time
Active malignancy (except for CTCL, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months
Serious intercurrent illness
Significant cardiac disease requiring ongoing treatment, including congestive heart failure (CHF), severe coronary artery disease (CAD), cardiomyopathy, uncontrolled cardiac arrhythmia, unstable angina pectoris, or myocardial infarction (MI)
Significant pulmonary symptoms or disease
History of uncontrolled seizure disorder or active central nervous system disease
Major surgery within 2 weeks of study enrollment
Significant or uncontrolled infections requiring systemic anti-infective therapy
Known human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
Females who are pregnant (positive urine test) or breastfeeding
Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note